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While previous studies have examined the association between vancomycin (VAN) exposure and MIC with regard to outcomes
in methicillin-resistant Staphylococcus aureus bacteremia (MRSA-B), none have explored if a relationship exists with the VAN
minimum bactericidal concentration (MBC). The objective of this study was to evaluate the VAN 24-h area under the curve
(AUC24)/MBC ratio as a pharmacodynamic predictor of mortality. This retrospective cohort study included patients treated with
VAN for MRSA-B with the primary outcome of 30-day all-cause mortality. Data collected included patient demographics, co-
morbidities, antimicrobial treatment data, therapeutic drug levels, and laboratory and microbiological data. Vancomycin MICs
and MBCs were determined by Etest (MIC only) and broth microdilution (BMD). The vancomycin AUC24 was determined by
pharmacokinetic maximum a posteriori probability Bayesian (MAP-Bayesian) analysis. The most significant breakpoint for 30-
day mortality was determined by classification and regression tree (CART) analysis. The association between pharmacodynamic
parameters (VAN AUC24/MICBMD, VAN AUC24/MICEtest, and AUC24/MBCBMD) and mortality were determined by 
2 and multi-
variable Poisson regression. Overall mortality in this cohort (n  53) was 20.8% (n  11/53), and all corresponding MRSA blood
isolates were VAN susceptible (MIC range, 0.5 to 2 g/ml; MIC50, 1 g/ml; MIC90, 1 g/ml). The CART-derived breakpoints for
mortality were 176 (VAN AUC24/MBC) and 334 (VAN AUC24/MICBMD). In multivariable analysis, the association between a
VAN AUC24/MBC of >176 and survival persisted, but VAN AUC24/MICBMD values (>334 or >400) were not associated with
improved mortality. In conclusion, VAN AUC24/MBC was a more important predictor of 30-day mortality than VAN AUC24/
MIC for MRSA-B.
The incidence of methicillin-resistant Staphylococcus aureus(MRSA) infections in health care and community settings has
increased in recent years (1). Vancomycin (VAN) has been a
mainstay in the armamentarium against MRSA for nearly half a
century, but changes in susceptibility patterns have presented new
treatment challenges (2). The gradual reduction in susceptibility
of MRSA isolates to VAN occurring over the last 2 decades has
been associated with increased treatment failure and mortality (3,
4). While the relationship between VAN MIC and clinical out-
comes in MRSA bacteremia (MRSA-B) is well established, the
importance of VAN minimum bactericidal concentration (MBC)
is less clear (5).
Multiple studies have highlighted the importance of bacteri-
cidal therapy in treating S. aureus bacteremia (SAB). Previous re-
search has demonstrated that in vitro 24-h bactericidal activity by
VAN is associated with a decrease in the duration of MRSA-B
clinically compared to in vitro bacteriostatic activity (6). Addition-
ally, decreased in vitro VAN killing activity over 72 h also has been
associated with an increase in 30-day mortality in patients with
MRSA-B treated with VAN (7). Sakoulas et al. reported an asso-
ciation between elevated VAN MIC and treatment failure but also
noted that reduced bactericidal activity had a similar effect (8).
Lastly, multiple studies have demonstrated improved clinical out-
comes with -lactam therapy compared to those with VAN for
methicillin-susceptible SAB, which may be partially attributed to
the superior killing activity of -lactams compared to that of VAN
(9, 10). Thus, there is evidence to suggest that VAN bactericidal
activity plays an influential role in clinical outcomes of SAB, in-
cluding MRSA-B.
Consensus recommendations support a VAN area under the
curve (AUC)/MIC ratio of 400 as a pharmacodynamic predictor
of therapeutic effectiveness for MRSA infections (11). An AUC/
MIC ratio of 421 also has been associated with clinical success in
MRSA-B (12). Due to the trend toward improved outcomes with
increased bactericidal activity of VAN, we hypothesized that VAN
exposure as a function of MBC rather than MIC may be a more
important predictor of VAN effectiveness in the treatment of
MRSA-B. Therefore, the objectives of this study were to (i) evalu-
ate the association between pharmacodynamic parameters (VAN
AUC24/MIC ratio determined by broth microdilution [MICBMD],
VAN AUC24/MIC ratio determined by Etest [MICEtest], and VAN
AUC24/MBC ratio) and 30-day mortality and (ii) quantify the
VAN AUC24/MBC threshold associated with an increased proba-
bility of mortality in a cohort of hospitalized patients with
MRSA-B.
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(This work was presented in part at the 54th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Washing-
ton, DC, 8 September 2014.)
MATERIALS AND METHODS
Study population and data sources. This was a retrospective study of
patients treated for MRSA-B at the University of Kansas Hospital, a ter-
tiary-care academic medical center, from September 2012 through June
2014. Inclusion criteria were (i) age of 18 years, (ii) positive blood cul-
ture for MRSA, and (iii) intravenous treatment with VAN. Patients were
excluded if they were on hemodialysis, had polymicrobial bacteremia at
onset, or were treated with VAN for 48 h. For patients with multiple
clinical MRSA blood isolates during the study period, only the first isolate
and corresponding clinical case of MRSA-B were evaluated. Clinical data
were collected by retrospective chart review. Variables abstracted in-
cluded baseline patient demographics, setting of bacteremia onset (com-
munity versus hospital-acquired [admission within 72 h]), comorbidi-
ties, Charlson comorbidity index, Pitt bacteremia score (PBS), acute
physiology and chronic health evaluation II (APACHE II) score, labora-
tory data (including VAN therapeutic drug monitoring), microbiology
data, antimicrobial treatment data (including previous VAN exposure
within 30 days), and vital signs. The focus of MRSA-B was determined as
documented by a treating physician and categorized according to mortal-
ity risk (13). Immunosuppression was defined as chronic steroid (equiv-
alent to 20 mg prednisone) or antineoplastic use, neutropenia, or leu-
kopenia. The primary clinical outcome was 30-day all-cause mortality.
This study was approved by the University of Kansas Medical Center
institutional review board.
AUC determination. Vancomycin AUC values were estimated with
ADAPT 5 software (University of Southern California, Los Angeles, CA,
USA). Using data from a previously published 2-compartment VAN
model, the mean parameter vector and full covariance matrix were em-
bedded into the PRIOR subroutine of ADAPT 5 (14, 15). For each indi-
vidual patient, the pharmacokinetic parameter values were estimated us-
ing the maximum a posteriori probability (MAP) procedure. After the
MAP-Bayesian step, values of the AUC for 0 to 72 h (AUC0 –72) and
AUC0 –96 were estimated for each patient. For the purposes of these anal-
yses, the AUC at 72 to 96 h (AUC24) of therapy was used, because this is the
24-h exposure variable that most closely resembles a steady-state AUC
(16). The vancomycin AUC24 was calculated as the difference in inte-
grated AUC0 –72 and AUC0 –96 values.
Microbiological analysis. (i) Bacterial strains. Clinical S. aureus
blood isolates from MRSA-B cases encountered during the study period
were stored at 70°C and passed for 3 consecutive days on tryptic soy agar
(TSA) to ensure uniform metabolic activity prior to testing.
(ii) Antimicrobials. Vancomycin was commercially purchased from
Sigma-Aldrich Co. (St. Louis, MO, USA). Stock solutions of VAN were
prepared daily.
(iv) Media. Mueller-Hinton II broth (Becton-Dickinson, Sparks, MD,
USA) was used as media for susceptibility testing. Brain heart infusion
agar (Becton-Dickinson, Sparks, MD, USA) was used as the medium for
the Etest. Tryptic soy agar (Becton-Dickinson, Sparks, MD, USA) was
used for colony counts.
(v) Susceptibility testing. Vancomycin MICs were determined by
broth microdilution (BMD) at concentrations of 0.125 to 64 g/ml at a
standard inoculum of approximately 1  106 CFU/ml according to Clin-
ical and Laboratory Standards Institute (CLSI) guidelines (17). The van-
comycin MIC also was determined for all isolates by Etest according to
manufacturer recommendations (bioMérieux, Marcy l’Etoile, France).
Staphylococcus aureus ATCC 25923 was used as the control strain, and
each test was performed in duplicate to ensure reproducibility.
(vi) MBC determination. Vancomycin MBCs were determined by the
microdilution method according to CLSI guidelines (18). To account for
antibiotic carryover, 100-l aliquots of all wells with no visible growth
after 24 h of incubation at 35°C (i.e., above the MICBMD endpoint) were
streaked onto TSA, allowed to visibly dry at room temperature, and cross-
streaked using a sterile cotton-tipped swab (18, 19). The vancomycin
MBC was defined as the lowest concentration with 99.9% killing after 24
h of incubation at 35°C. Vancomycin tolerance was defined as a MBC/
MIC ratio of 32.
Statistical analysis. Categorical variables were compared by 2 or
two-tailed Fisher’s exact test, and continuous variables were compared by
t test or Mann-Whitney U test. The AUC24 variable was divided by
MICBMD, MICEtest, and MBC, respectively, to compute the VAN pharma-
codynamic variables of interest. Classification and regression tree (CART)
analyses were used to identify the breakpoints in these pharmacodynamic
parameters associated with an increased probability of the primary out-
come (30-day mortality). A secondary analysis examining the relationship
between VAN exposure within the preceding 30 days and VAN MICBMD
and MBC was performed using the Cochran-Armitage trend test.
The association between VAN pharmacodynamic parameters and
clinical outcomes was evaluated using backward stepwise Poisson regres-
sion with CART-derived breakpoints forced into respective models. Vari-
ables which were associated with the pharmacodynamic parameter of in-
terest or 30-day mortality (P  0.2) were entered into the model, and only
those that confounded the relationship between the pharmacodynamic
breakpoint and 30-day mortality (10% change in the associated risk
ratio) were retained in the final parsimonious model. The association
between the guideline concordant VAN AUC24/MICBMD target of 400
and 30-day mortality also was evaluated in this cohort (11). Time-to-
event analyses were conducted for 30-day mortality using the Kaplan-
Meier method and log-rank test. Survivors were right-censored at the end
of treatment with VAN, and backward stepwise Cox regression was per-
formed. Statistical analyses were performed using SAS (version 9.2; SAS
Institute, Inc., Cary, NC, USA), and a two-tailed P value of 0.05 was
considered statistically significant for all tests.
RESULTS
During the study period, a total of 100 patients with MRSA-B who
were treated with VAN were identified. Patients were excluded
due to treatment with VAN for 48 h (n  13) and due to hemo-
dialysis (n  34). The final analysis included a total of 53 patients.
All corresponding clinical MRSA blood isolates were VAN suscep-
tible (MIC range, 0.5 to 2 g/ml; MIC50, 1 g/ml; MIC90, 1 g/
ml). Among these isolates, 13/53 (24.5%) were VAN tolerant
(MBC range, 0.5 to 64 g/ml; MBC50, 1 g/ml; MBC90, 64 g/ml).
Additionally, 25/53 (47.2%) of clinical MRSA isolates had disso-
ciated MICBMD and MBC values.
Overall, 30-day mortality was 20.8% (n  11/53). Factors as-
sociated with 30-day mortality among MRSA-B patients treated
with VAN are included in Table 1. In univariable analysis, mean
age, an age of 85 years, previous VAN exposure within 30 days,
intensive care unit (ICU) admission, high-risk infection focus,
malignancy, median Charlson comorbidity index, PBS, and
APACHE II score were significantly associated with increased 30-
day mortality. Conversely, a medium-risk focus of infection was
associated with decreased 30-day mortality.
In this cohort, the mean duration of VAN therapy was 8.73
days (standard deviations [SD], 5.23 days). The mean VAN AUC24
at steady state [AUC24(ss)] was 681 mg · h/liter (SD, 331 mg · h/liter).
The median VAN AUC24(ss) was 661.7 mg · h/liter (interquartile
range, 440.6 to 834.1 mg · h/liter). The CART-derived 30-day
mortality breakpoints were 334 for VAN AUC24/MICBMD ratio
and 176 for VAN AUC24/MBC ratio. Classification and regression
tree analysis yielded no optimal breakpoint for the association
between AUC24/MICEtest and 30-day mortality, so no further
analyses were conducted for this parameter. In univariable analy-
sis, mortality was significantly lower when the VAN AUC24/
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MICBMD was 334 (7.7% [n  2/26] versus 33.3% [n  9/27];
P  0.021) and when the VAN AUC24/MICBMD was 400 (14.3%
[n  6/42] versus 45.5% [n  5/11]; P  0.037). Mortality also
was significantly lower when the VAN AUC24/MBC was 176
(9.4% [n  3/32] versus 38.1% [n  8/21]; P  0.017). Compar-
isons of baseline patient characteristics by CART-derived break-
points are displayed in Tables 2 and 3. As shown, there were many
significant differences between groups with regard to these char-
acteristics. In the secondary trend analysis, prior VAN exposure
within 30 days was associated with a linear increase in VAN
MICBMD (P  0.033) and VAN MBC (P  0.001).
The association between pharmacodynamic parameters and
30-day mortality were evaluated in multivariable Poisson regres-
sion analyses (Table 4). As shown, the association between a VAN
AUC24/MBC ratio of 176 and 30-day mortality persisted after
adjusting for age, malignancy, PBS, and cirrhosis (Table 4, model
1). After adjusting for confounding factors, VAN AUC24/MICBMD
ratios of 334 and 400 were not significantly associated with
mortality in this cohort (Table 4, models 2 and 3).
In Kaplan-Meier analysis, the CART-derived VAN AUC24/
MBC breakpoint of 176 was significantly associated with im-
proved survival (P  0.011 by log-rank test). When evaluated by
multivariable Cox regression, the association between an AUC24/
MBC ratio of 176 and improved survival persisted (adjusted
hazard ratio [aHR], 7.32; 95% confidence interval [CI], 1.66 to
32.29; P  0.009) after adjusting for APACHE II score (aHR, 1.09;
95% CI, 1.01 to 1.19; P  0.042) and PBS of 4 (aHR, 6.80, 95%
CI, 1.68 to 27.60; P  0.007).
DISCUSSION
The present investigation aimed to evaluate the relationship be-
tween various VAN pharmacodynamic parameters and 30-day
mortality in MRSA-B. Primarily, we sought to derive an associated
VAN AUC24/MBC breakpoint and evaluate this breakpoint
alongside other pharmacodynamic parameters in a series of mul-
tivariable analyses. To our knowledge, this is the first study to
establish a VAN AUC24/MBC breakpoint for 30-day mortality.
Multiple studies have derived VAN AUC/MIC breakpoints, and
current consensus recommendations target a VAN AUC/MIC ra-
tio of 400 to maximize therapeutic effectiveness, although this
goal is only clinically feasible with some MIC values in the suscep-
TABLE 1 Factors associated with 30-day mortality among MRSA-B
patients treated with VAN
Factora






Age (yr), means 	 SD 58.5 	 15.9 70.6 	 16.6 0.031
65 yr, n (%) 17 (40.5) 7 (63.6) 0.170
85 yr, n (%) 1 (2.4) 3 (27.3) 0.025
Female gender, n (%) 15 (35.7) 3 (27.3) 0.730
Previous VAN exposure within 30
days, n (%)
4 (9.5) 5 (45.5) 0.031
Hospital-acquired MRSA-B, n (%) 12 (28.6) 6 (54.5) 0.105
ICU, n (%) 10 (23.8) 6 (54.5) 0.048
Sepsis, n (%) 27 (64.3) 9 (81.8) 0.267
Septic shock, n (%) 6 (14.3) 2 (18.2) 0.665
Immunosuppression, n (%) 10 (23.8) 4 (36.4) 0.453
MRSA-B focus
High risk, n (%) 10 (23.8) 8 (72.7) 0.002
Medium risk, n (%) 26 (61.9) 2 (18.2) 0.016
Low risk, n (%) 6 (14.3) 1 (9.1) 1.000
MRSA bacteriuria, n (%) 4 (9.5) 1 (9.1) 1.000
Diabetes mellitus, n (%) 15 (35.7) 4 (36.4) 0.968
Alcoholism, n (%) 4 (9.5) 1 (9.1) 1.000
Cirrhosis, n (%) 3 (7.1) 1 (9.1) 1.000
Congestive heart failure, n (%) 3 (7.1) 2 (18.2) 0.275
Malignancy, n (%) 8 (19.0) 7 (63.6) 0.003
HIV positive, n (%) 1 (2.4) 0 (0.0) 1.000
Chronic obstructive pulmonary
disease, n (%)
5 (11.9) 2 (18.2) 0.626
Charlson comorbidity index,
median (IQR)
6 (3–7) 7 (6–9) 0.017
PBS, median (IQR) 1 (0–3) 4 (1–6) 0.028
PBS  4, n (%) 7 (16.7) 6 (54.5) 0.009
APACHE II score, median (IQR) 11 (7–14) 17 (14–25) 0.002
a IQR, interquartile range.
TABLE 2 Patient characteristics by CART-derived AUC24/MBC









Age (years), means 	 SD 67.6 	 15.5 55.2 	 15.9 0.007
65 yr, n (%) 13 (61.9) 11 (34.4) 0.049
85 yr, n (%) 4 (19.0) 0 (0.0) 0.020
Female gender, n (%) 6 (28.6) 12 (37.5) 0.502
Previous VAN exposure within 30
days, n (%)
7 (33.3) 2 (6.2) 0.021
Hospital-acquired MRSA-B, n (%) 11 (52.4) 7 (21.9) 0.022
ICU, n (%) 8 (38.1) 8 (25.0) 0.310
Sepsis, n (%) 16 (76.2) 20 (62.5) 0.296
Septic shock, n (%) 6 (28.6) 2 (6.2) 0.047
Immunosuppression, n (%) 4 (19.0) 10 (31.2) 0.324
MRSA-B focus, n (%)
High risk 10 (47.6) 8 (25.0) 0.089
Medium risk 7 (33.3) 21 (65.6) 0.021
Low risk 4 (19.0) 3 (9.4) 0.415
MRSA bacteriuria, n (%) 2 (9.5) 2 (9.4) 1.000
Diabetes mellitus, n (%) 7 (33.3) 12 (37.5) 0.757
Alcoholism, n (%) 1 (4.8) 4 (12.5) 0.637
Cirrhosis, n (%) 0 (0.0) 4 (12.5) 0.143
Congestive heart failure, n (%) 5 (23.8) 0 (0.0) 0.007
Malignancy, n (%) 7 (33.3) 8 (25.0) 0.546
HIV positive, n (%) 0 (0.0) 1 (3.1) 1.000
Chronic obstructive pulmonary
disease, n (%)
4 (19.0) 3 (9.4) 0.415
Charlson comorbidity index,
median (IQR)
7 (5–9) 6 (3–7) 0.058
PBS, median (IQR) 2 (1–4) 2 (0–4) 0.528
PBS  4, n (%) 5 (23.8) 8 (25.0) 0.922
APACHE II, median (IQR) 13 (9–18) 10 (7–15) 0.084
a IQR, interquartile range.
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tible range (11, 12, 16). In the present investigation, a VAN
AUC24/MICBMD ratio of 334 and VAN AUC24/MICBMD ratio
of 400 both were significantly associated with improved mortal-
ity in univariable analysis. However, the CART-derived VAN
AUC24/MBC breakpoint of 176 was the only pharmacodynamic
parameter that was significantly associated with improved mor-
tality after adjusting for confounding factors. A vancomycin
AUC24/MBC ratio of 176 also was associated with improved
survival in Kaplan-Meier analysis and multivariable Cox regres-
sion.
The association between VAN MIC and clinical outcomes has
been evaluated exhaustively in the literature, while little attention
has been paid to the potential importance of bactericidal activity
(3, 5). Studies that have evaluated VAN bactericidal activity have
noted an apparent association between reduced bactericidal activ-
ity and worse clinical outcomes (7, 8). Although VAN MIC and
MBC values are correlated, it is not uncommon for these values to
be either slightly or greatly dissociated (20–22). In the present
study, nearly half of corresponding MRSA isolates had some level
of dissociation between VAN MICBMD and MBC. Because bacte-
ricidal activity is preferred in the treatment of MRSA-B, a VAN
AUC24/MIC target theoretically would be less likely to predict
therapeutic effectiveness when MIC and MBC values are dissoci-
ated (6). Vancomycin AUC24/MBC estimations would allow for
the differentiation of these cases and potentially provide a more
sensitive predictor of VAN effectiveness. The results of the present
study appear to support this logic.
The finding that prior VAN exposure can influence VAN ac-
tivity as well as clinical outcomes in MRSA-B is consistent with
previous research (23, 24). This observation potentially has signif-
icant clinical implications in the treatment of MRSA-B, as previ-
ous VAN exposure was associated with increased VAN MICBMD
and VAN MBC and a lower probability of achieving optimal
AUC24/MICBMD and AUC24/MBC ratios in univariable analysis.
Therefore, alternatives to VAN may be warranted for treatment of
MRSA-B in patients with recent VAN exposure, even if the corre-
sponding isolate tests susceptible.
The utility of the VAN AUC24/MBC ratio as a pharmacody-
namic predictor of VAN effectiveness likely is dependent on the
prevalence of dissociated VAN MIC and MBC values, including
VAN tolerance. The prevalence of VAN tolerance is approxi-
mately 20% among MRSA blood isolates, although tolerance is as
high as 43% in some institutions (21). Therefore, the proportion
of VAN tolerant isolates observed in the present study is consistent
with previous research and likely similar to tolerance rates typi-
cally found in U.S. hospitals. In institutions where VAN tolerance
is more common, the difference between AUC24/MIC and
AUC24/MBC targets likely would be even more profound. It
should be noted that AUC72–96 was used in this study as a measure
of 24-h VAN exposure. The decision to select VAN AUC72–96 was
informed by the literature (16). Furthermore, the vast majority of
patients will have achieved steady-state concentrations of VAN
and most clinicians will have commenced VAN therapeutic drug
monitoring by this time point. Unfortunately, the literature is not
clear regarding the optimal VAN AUC time interval for predicting
clinical outcomes, and this question should be addressed in future
studies (16, 25–27).
TABLE 3 Patient characteristics by CART-derived AUC24/MICBMD









Age (yr), means 	 SD 63.5 	 19.1 56.5 	 13.5 0.136
65 yr, n (%) 14 (51.9) 10 (38.5) 0.328
85 yr, n (%) 4 (14.8) 0 (0.0) 0.111
Female gender, n (%) 8 (29.6) 10 (38.5) 0.497
Previous VAN exposure within 30
days, n (%)
8 (29.6) 1 (3.8) 0.024
Hospital-acquired MRSA-B, n (%) 12 (44.4) 6 (23.1) 0.101
ICU, n (%) 10 (37.0) 6 (23.1) 0.268
Sepsis, n (%) 20 (74.1) 16 (61.5) 0.328
Septic shock, n (%) 7 (25.9) 1 (3.8) 0.050
Immunosuppression, n (%) 6 (22.2) 8 (30.8) 0.480
MRSA-B focus, n (%)
High risk 12 (44.4) 6 (23.1) 0.101
Medium risk 11 (40.7) 17 (65.4) 0.072
Low risk 4 (14.8) 3 (11.5) 0.725
MRSA bacteriuria, n (%) 2 (7.4) 3 (11.5) 0.669
Diabetes mellitus, n (%) 9 (33.3) 10 (38.5) 0.697
Alcoholism, n (%) 1 (3.7) 4 (15.4) 0.192
Cirrhosis, n (%) 0 (0.0) 4 (15.4) 0.051
Congestive heart failure, n (%) 5 (18.5) 0 (0.0) 0.051
Malignancy, n (%) 9 (33.3) 6 (23.1) 0.407
HIV positive, n (%) 1 (3.7) 0 (0.0) 1.000
Chronic obstructive pulmonary
disease, n (%)
4 (14.8) 3 (11.5) 0.725
Charlson comorbidity index,
median (IQR)
7 (5–9) 5 (3–7) 0.099
PBS, median (IQR) 2 (1–4) 2 (0–3) 0.238
PBS  4, n (%) 7 (25.9) 6 (23.1) 0.810
APACHE II, median (IQR) 13 (6–17) 11 (8–14) 0.232
a IQR, interquartile range.
TABLE 4 Poisson regression models for 30-day mortality by
pharmacodynamic parameter among MRSA-B patients
Model and characteristic
Adjusted risk
ratio (95% CI) P value
Model 1
VAN AUC24/MBC  176 3.68 (1.17–11.56) 0.025
Age 85 yr 4.24 (1.75–10.23) 0.001
Malignancy 5.62 (2.31–13.65) 0.001
PBS  4 3.63 (1.48–8.67) 0.005
Cirrhosis 6.33 (0.60–67.38) 0.120
Model 2
VAN AUC24/MICBMD  334 5.12 (0.85–30.67) 0.074
Malignancy 3.70 (1.25–10.97) 0.019
MRSA pneumonia 3.56 (1.13–11.26) 0.031
Cirrhosis 9.88 (0.72–34.79) 0.086
Model 3
VAN AUC/MICBMD  400 1.95 (0.92–4.15) 0.084
Malignancy 3.89 (1.31–11.53) 0.014
MRSA pneumonia 3.59 (1.16–11.11) 0.026
Cirrhosis 3.73 (0.39–36.07) 0.255
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The present investigation has a number of noteworthy limita-
tions. Most notably, this was a retrospective analysis and suffers
from the limitations of such a design. Although the VAN AUC24/
MICBMD ratio was not predictive of 30-day mortality in this co-
hort after adjusting for other factors, there is a concern for type II
error due to the relatively small number of patients included. It is
important to consider that the utility of the VAN AUC24/MBC
ratio as a pharmacodynamic predictor of VAN effectiveness likely
will depend on institution-specific VAN tolerance rates, which
may not be known. Previous research has demonstrated that other
phenotypic characteristics of MRSA, such as biofilm formation
and susceptibility to host defense cationic peptide, play an influ-
ential role in clinical outcomes of MRSA-B (28). Although the
purpose of this study was to investigate the relationship between
VAN AUC24/MBC ratios and clinical outcomes, it is important to
consider the possible influence of unmeasured phenotypic and
genotypic microbiological characteristics (28, 29). Host defense
cationic peptide phenotypes have been associated with reduced
susceptibility to vancomycin and defective autolytic mechanisms
(30). These phenotypic changes, in addition to enhanced biofilm
production, have been associated with poor clinical outcomes in
MRSA-B, including persistent infection (20, 28, 30). Additionally,
the cause of death was not known and we were unable to ascertain
attributable mortality. Important strengths of this study were the
utilization of a method for MBC testing which appropriately ac-
counted for antibiotic carryover, use of a MAP-Bayesian approach
to determine VAN AUC24, and application of CART analysis to
define a novel VAN AUC24/MBC breakpoint for 30-day mortality.
In summary, the VAN AUC24/MBC was a more important
predictor of 30-day mortality than the VAN AUC24/MICBMD in a
cohort of patients with MRSA-B. The VAN AUC24/MBC break-
point most predictive of survival was 176. Overall, the results of
this study add to the growing body of literature underscoring the
importance of VAN bactericidal activity in the treatment of
MRSA-B. Alternatives to VAN may be warranted in cases of
MRSA-B where the achievement of optimal AUC24/MBC is un-
likely, such as in patients with VAN-tolerant clinical isolates or
recent VAN exposure. This research should be replicated in a
larger analysis and at institutions with various rates of VAN toler-
ance.
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